

ANB032, a BTLA (B and T Cell Lymphocyte Attenuator) Checkpoint Receptor Agonist, Modulates Dendritic Cell Maturation and Function


Pejman Soroosh, Eric Hare, Stephen Parmley, Paul Lizzul, Martin Dahl
AnaptysBio, San Diego, CA, USA

ABSTRACT


BTLA is a co-inhibitory checkpoint receptor that regulates T cell, B cell and DC function. The interaction of BTLA with its ligand, HVEM, induces inhibitory signals that regulate immune cell function. ANB032, an investigational non-depleting BTLA agonist antibody, does not compete with the binding of BTLA to HVEM. Previous *in vitro* studies demonstrated that upon binding to BTLA and simultaneous Fc receptor engagement to an opposing cell, ANB032 induced inhibitory signaling, reduced T cell proliferation, and reduced inflammatory cytokine secretion (Th1, Th2, Th17, Th22). Although the expression of BTLA on subsets of DCs has been reported, BTLA's role in modulating DC maturation and function has not been thoroughly investigated. To address the functional role of BTLA on DCs, an LPS-mediated maturation assay with monocyte-derived DCs was performed to confirm that mature DCs highly express BTLA. ANB032 reduced HLA-DR expression, co-stimulatory molecule expression, and inhibited inflammatory cytokine production from DCs challenged with LPS. When co-cultured with allogenic naive T cells, ANB032-treated DCs increased the generation of Foxp3+ Tregs and decreased production of Th1 and Th2 cytokines. Therefore, BTLA agonism by ANB032 inhibits a broad range of immune cells and modulates DC function, while inducing Tregs, and potentially restoring immune balance, which may provide therapeutic value in the treatment of autoimmune and inflammatory disease. ANB032 is currently being studied in a Phase 2 clinical trial in atopic dermatitis (NCT05935085).

BACKGROUND & OBJECTIVE

- AD is a systemic, heterogenous inflammatory disease with pathogenesis driven by Th1, Th2, Th17, Th22, and DCs both in skin and the periphery
- There are significantly more DCs in the skin of AD patients, with up to 10-fold increase in the epidermis and up to 3.5-fold increase in the dermis²
- BTLA is a co-inhibitory checkpoint receptor expressed preferentially on activated T cells, B cells, and DCs, key contributors to inflammatory diseases
- Preclinical studies demonstrated that BTLA-deficient mice show increased T cell proliferation and susceptibility to spontaneous development of autoimmune diseases, including dermatitis, further supporting data that BTLA negatively regulates T cell activation and proliferation^{3,4}
- Although the expression of BTLA on subsets of DCs has been reported, BTLA's role in modulating DC maturation and function has not been thoroughly investigated
- ANB032 is an investigational non-depleting BTLA agonist that does not compete with the binding of BTLA to herpesvirus entry mediator (HVEM), its ligand (Figure 1)



Proposed Mechanism of Action for ANB032



BTLA is a key node of immune regulation

- BTLA is a potent co-inhibitory checkpoint receptor
- Expressed only on immune cells and preferentially on activated immune cells
- Dysregulation of BTLA pathway accelerates onset and exacerbates disease

ANB032: IgG4 antibody (non-depleting)

- Binds BTLA proximal to immune cell
- Fc receptor binding contributes to differentiated potency
- Non-blocking of HVEM engagement

Figure 1. Schematic of proposed MOA

Objective: Investigate the role of BTLA and effect of ANB032 on DC maturation and activation in a preclinical model

METHODS

BTLA expression on DCs:

- Purified monocytes from healthy PBMCs were differentiated to DCs
- Differentiated DCs were either stimulated with lipopolysaccharide (LPS) or rested in fresh medium, then stained for MHC II and CD11c, and the BTLA expression was evaluated on immature and mature DCs

Effect of ANB032 on DCs:

- Differentiated DCs were treated with either ANB032 or isotype control, then stimulated with LPS and stained for MHC II and CD11c to evaluate the maturation state of DCs, absolute number of mature DCs, expression of MHC II and activation markers

Effect of ANB032 on Tregs and inflammatory cytokines:

- Differentiated DCs were treated with either ANB032 or isotype control
- ANB032-treated DCs were washed and then co-cultured with allogenic naive CD4 T cells, then T cells were stained for CD4, CD25, and intracellular Foxp3 to identify inducible regulatory T cells (iTreg)
- The frequency of differentiated iTregs and secretion of inflammatory cytokines were evaluated by FACS and MSD, respectively

RESULTS

BTLA was Highly Expressed on Mature DCs with LPS Stimulation

- LPS-stimulated DCs resulted in 40% mature and 50% immature DCs
- BTLA expression was seen in 92.7% of mature DCs versus 9.3% of immature DCs (Figure 2)






Figure 2. BTLA expression on DCs

ANB032 Inhibits DC Maturation and Reduces Antigen Presentation and Co-Stimulatory Molecules



After treatment with either ANB032 or the isotype control, maturation of both mature and immature LPS-stimulated DCs were inhibited and the absolute number of mature DCs was substantially less than control



ANB032-treated DCs had lower expression of MHC II relative to the isotype control, indicating a reduction in antigen presentation with ANB032





Figure 3. Effect of ANB032 on DC maturation (A), MHC II presentation (B), and co-stimulatory molecule expression (C)

ANB032-treated DCs Induce Functional Tregs



DCs were treated with either ANB032 or isotype and then co-cultured with allogenic naive CD4 T cells to allow T cell differentiation. T cells were stained for CD4, CD25 and intracellular Foxp3 to identify inducible Tregs




Figure 4. Effect of ANB032-treated DCs on functional Tregs (A) and cytokine secretion (B)

CONCLUSIONS

- BTLA is highly expressed on mature DCs
- Preclinical evaluation of ANB032 demonstrated:
 - Inhibition of DC maturation and reduction of antigen presentation and co-stimulatory molecule expression
 - Modulation of DC function to boost inducible Foxp3+ Tregs and inhibit effector T cells and inflammatory cytokine production
 - Inhibition of a broad range of immune cells, including DCs, while inducing Tregs, which supports a potential for restoring immune balance
- Based on these findings, ANB032 may provide therapeutic value in the treatment of autoimmune and inflammatory diseases, including AD
- A double-blind, placebo-controlled, global Phase 2 study of ANB032 in moderate-to-severe AD is actively enrolling participants (NCT05935085)

ACKNOWLEDGEMENTS

- This research was funded by Anaptys
- Disclosures: All authors are employees and stockholders of Anaptys
- Cynthia Alexander of Anaptys provided medical writing support
- This poster was previously presented at the American Academy of Dermatology meeting in March 2024

REFERENCES

- Luu, et al. Presented at ISID 2023
- Guttman-Yassky, et al. J Allergy Clin Immunol 2007;119:1210-7.
- Nakagomi et al. J Invest Dermatol 2013;133:702-11.
- Bekiaris et al. Immunity 2013;39:1082-94.

